Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
138.77
+7.43 (5.66%)
At close: Oct 9, 2026, 4:00 PM EDT
139.99
+1.22 (0.88%)
After-hours: Oct 9, 2026, 6:57 PM EDT
Company Description
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis.
The company is based in Wayne, Pennsylvania.
Palvella Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Wesley Kaupinen |
Contact Details
Address: 353 W. Lancaster Avenue, Suite 200 Wayne, Pennsylvania 19087 United States | |
| Phone | 484 253 1461 |
| Website | palvellatx.com |
Stock Details
| Ticker Symbol | PVLA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001583648 |
| CUSIP Number | 697947109 |
| ISIN Number | US6979471090 |
| Employer ID | 30-0784346 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Wesley H. Kaupinen | Founder, President, Chief Executive Officer and Director |
| Matthew E. Korenberg | Chief Financial Officer, Corporate Secretary and Treasurer |
| Kathleen Goin | Chief Operating Officer |
| Dr. Jeffrey Martini Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 16, 2026 | 144 | Filing |
| Sep 11, 2026 | 144 | Filing |
| Sep 2, 2026 | 144 | Filing |
| Aug 19, 2026 | 144 | Filing |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 10, 2026 | SCHEDULE 13G | Filing |
| Aug 4, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 4, 2026 | 10-Q | Quarterly Report |
| Aug 4, 2026 | 8-K | Current Report |